$17M Revance Therapeutics Securities Merger Settlement, Check If You Qualify for a Payment August 28 is Deadline

Prepared by the AllAboutLawyer.com Editorial Team and reviewed for factual accuracy against the official settlement notice and court records filed in In re Revance Therapeutics, Inc. Securities Litigation, Case No. 3:25-cv-0018-EJR (M.D. Tenn.). Last Updated: May 12, 2026

The Revance Therapeutics Securities Settlement is a federal securities class action where eligible investors who purchased Revance common stock (RVNC) or 1.75% Convertible Senior Unsecured Notes between February 29, 2024, and February 6, 2025, can receive a cash payment by filing a claim before August 28, 2026.

Revance Therapeutics Inc.’s $17 million agreement with investors earned a federal judge’s initial blessing to resolve allegations that the anti-wrinkle injection developer hid that it might be in breach of a dermal-filler distribution contract — a breach that ultimately caused its buyout price to collapse. The settlement received preliminary court approval on April 10, 2026.

Quick-Facts: Revance Therapeutics $17M Securities Settlement

Field	Detail
Settlement Amount	$17,000,000
Claim Deadline	August 28, 2026
Who Qualifies	Purchasers of RVNC common stock or 1.75% Convertible Senior Notes, Feb 29, 2024 – Feb 6, 2025
Payout Per Person	Est. $0.16 per damaged common share; est. $10.26 per damaged note (before fees)
Proof Required	Yes — brokerage statements or trade confirmations
Settlement Status	Preliminarily Approved — Final hearing Aug 10, 2026
Administrator	A.B. Data, Ltd. — (877) 507-1390
Official Website	RevanceSecuritiesSettlement.com
Last Updated	May 12, 2026

Current Status of the Revance Settlement

• The U.S. District Court for the Middle District of Tennessee granted preliminary approval on April 10, 2026. The final fairness hearing is scheduled for August 10, 2026, at 9:00 a.m. Central time before Judge Eli J. Richardson.
• The deadlines to opt out of the settlement or file a written objection are both July 13, 2026.
• Payments will go out only after the court grants final approval at the August 10 hearing and resolves any appeals. No confirmed distribution date exists yet — TBD pending final court approval.

What Is the Revance Lawsuit About? In re Revance Therapeutics, Inc. Securities Litigation, No. 3:25-cv-0018-EJR

Revance Therapeutics was a Nashville-based biotech company that developed Daxxify, a botulinum toxin (Botox competitor) and held the exclusive U.S. distribution rights for Teoxane’s line of hyaluronic acid dermal fillers. In August 2024, Revance and Crown Laboratories, Inc. — a privately held skincare products company — announced a merger agreement under which Crown would acquire all outstanding Revance shares for $6.66 per share in cash, representing a total enterprise value of approximately $924 million.

The lawsuit alleges that throughout the class period, Revance failed to disclose it was in material breach of its distribution agreement with Teoxane SA, that this breach exposed the company to increased litigation and reputational harm, and that it materially increased the risk the Crown tender offer would be delayed or drastically repriced. This is precisely the kind of investor securities fraud scenario that federal securities law is designed to prevent — artificially propping up a stock price by hiding information that would send it lower.

On December 9, 2024, Revance disclosed that Crown had amended the merger agreement and would commence a tender offer to acquire all outstanding shares for just $3.10 per share in cash — a drop of more than 50% from the original price. Investors who bought shares expecting a $6.66 deal were blindsided. The lawsuit alleges they would never have paid those prices had Revance disclosed its Teoxane contract problems upfront.

Related article: $1M Equity Bank Overdraft and NSF Fees Settlement, Check If You Qualify No Claim Form Required for Automatic Payment

The consolidated complaint, filed June 18, 2025, alleges Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and SEC Rule 10b-5. The defendants named are Revance Therapeutics, Inc., CEO Mark J. Foley, and CFO Tobin C. Schilke. If you want to understand how securities fraud class actions like this one work generally, the AllAboutLawyer.com guide to investor class action lawsuits walks through the full process.

Who Qualifies for the Revance Securities Settlement?

If you traded Revance securities during the class period, here is how to know whether you are in.

You may qualify if:

• You purchased or acquired Revance common stock (RVNC, CUSIP: 761330109) at any point between February 29, 2024, and the close of trading on February 6, 2025, inclusive.
• You purchased or acquired Revance 1.75% Convertible Senior Unsecured Notes (CUSIP: 761330AB5) during the same class period.
• You held the securities over at least one of the corrective disclosure dates (September 16, September 23, October 25, November 8, December 9, 2024, or February 6, 2025) and experienced a recognized loss as a result.
• You are an individual investor, pension fund, institutional investor, or other entity — the class action settlement eligibility is broad.

You do NOT qualify if:

• You are a current or former director or officer of Revance or Crown Laboratories who served in that role at any time after February 28, 2024.
• You are Crown Laboratories, Inc. itself, or any entity in which an excluded person holds a majority stake.
• You purchased and sold your shares entirely before September 16, 2024, without holding through any corrective disclosure — your recognized loss under the plan of allocation would be $0.
• You already submitted a valid exclusion request that the court accepted.

Related: Driven Brands $25M Securities Settlement — How to File a Claim

How Much Can You Get from the Revance Settlement?

The total settlement fund is $17,000,000 in cash, plus interest earned. Assuming all eligible class members participate, the estimated average recovery is $0.16 per damaged common share and $10.26 per damaged note, before deductions for attorneys’ fees and expenses.

Your actual legal settlement payout could be more or less than these averages, depending on several factors:

• Which specific dates you bought and sold
• Whether you held through one or more of the corrective disclosure events
• The total number of valid claims submitted by other class members (pro-rata distribution)

Lead Counsel plans to request attorneys’ fees of up to 33% of the $17 million settlement, plus litigation expenses not to exceed $250,000. If the court approves maximum fees, the estimated cost reduces the per-share recovery to approximately $0.10 per damaged common share and $7.27 per damaged note.

No distribution will be made to any claimant whose calculated payment is less than $10.00.

Step-by-Step: How to File Your Revance Claim Form

Here is exactly how to file your Revance securities settlement claim — it takes roughly 10–15 minutes if you have your brokerage records ready.

Step 1 — Visit RevanceSecuritiesSettlement.com and click the online claim form link.

Step 2 — Enter your personal information: name, address, taxpayer ID or Social Security number, and contact details.

Step 3 — List every purchase and sale of Revance common stock or notes during the class period (February 29, 2024 – February 6, 2025), including dates, number of shares or notes, and prices paid.

Step 4 — Upload supporting documentation — brokerage confirmation slips or monthly brokerage account statements showing your transactions and holdings.

Step 5 — Review your submission for accuracy. Small errors in trade dates or prices can reduce your recognized loss amount.

Step 6 — Submit your claim and save your confirmation number for your records.

Your claim must be postmarked or submitted online no later than August 28, 2026. You can also request a paper claim form by calling the administrator toll-free at (877) 507-1390.

Estimated time to complete: 10–15 minutes.

Revance Settlement Key Dates

Milestone	Date
Class Period Begins	February 29, 2024
Class Period Ends	February 6, 2025
Lawsuit Filed	January 3, 2025
Settlement Agreement Reached	February 1, 2026
Preliminary Approval Granted	April 10, 2026
Opt-Out / Objection Deadline	July 13, 2026
Final Approval Hearing	August 10, 2026
Claim Filing Deadline	August 28, 2026
Expected Payment Date	TBD — pending final court approval and resolution of any appeals

Frequently Asked Questions

Is there a class action lawsuit against Revance Therapeutics?

 Yes. The case is In re Revance Therapeutics, Inc. Securities Litigation, Case No. 3:25-cv-0018-EJR, pending in the U.S. District Court for the Middle District of Tennessee. The parties reached a $17 million settlement agreement on February 1, 2026, and the court preliminarily approved it on April 10, 2026.

Do I need a lawyer to file a Revance settlement claim?

 No. You can file directly at RevanceSecuritiesSettlement.com without hiring an attorney. Attorneys’ fees are paid from the settlement fund itself — not from your individual payment — and Lead Counsel is requesting up to 33% of the $17 million total. A free legal consultation with a securities attorney is an option if your losses are large and you are considering opting out to pursue your own case.

How much will I get from the Revance settlement? 

The estimated average recovery is $0.16 per damaged common share and $10.26 per damaged note, before attorneys’ fees. Your actual amount depends on your specific purchase and sale dates, whether you held through corrective disclosure events, and how many other investors file valid claims.

What if I missed the Revance claim deadline?

 The claim deadline is August 28, 2026. If you miss it, you will receive no payment but will still be bound by the settlement’s release of claims against Revance, Mark Foley, and Tobin Schilke — unless you timely excluded yourself by July 13, 2026.

When will I receive my Revance settlement payment?

 TBD — payment will go out only after Judge Richardson grants final approval at the August 10, 2026 hearing and any appeals are resolved. Securities settlement distributions typically take several months after final approval.

Will my Revance settlement payment be taxable?

 Possibly. Settlement payments in securities fraud cases may be treated as taxable income depending on your individual circumstances. The settlement administrator is not in a position to give tax advice — consult a tax professional before filing your return for the year you receive payment.

What did Revance do wrong, exactly? 

The lawsuit alleges Revance was secretly in material breach of its distribution agreement with Teoxane SA while publicly presenting the Crown merger as a straightforward transaction at $6.66 per share. When that breach surfaced, Crown slashed its offer by more than 50%, and shareholders who bought in at higher prices lost money they would not have lost had Revance disclosed the problem upfront.

Can I still opt out of the Revance settlement? 

Yes, but only if your exclusion request is received by July 13, 2026. To opt out, mail a signed letter to: Revance Securities Settlement, c/o A.B. Data, Ltd., EXCLUSIONS, P.O. Box 173001, Milwaukee, WI 53217. Opting out means you receive no settlement payment but retain the right to sue Revance independently.

Sources & References

• Official Settlement Notice (Long-Form): RevanceSecuritiesSettlement.com
• Online Claim Form: RevanceSecuritiesSettlement.com/file-online-claim-form
• Court Docket — PACER: In re Revance Therapeutics, Inc. Securities Litigation, Case No. 3:25-cv-0018-EJR, U.S. District Court, Middle District of Tennessee

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.